[1] Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report:primary brain and other central nervous system tumors diagnosed in the united states in 2011-2015[J]. Neuro Oncol, 2018, 20:iv1-86.
[2] Colli LM, Machiela MJ, Myers TA, Jessop L, Yu K, Chanock SJ. Burden of nonsynonymous mutations among TCGA cancers and candidate immune checkpoint inhibitor responses[J]. Cancer Res, 2016, 76:3767-3772.
[3] Tran TT, Uhl M, Ma JY, Janssen L, Sriram V, Aulwurm S, Kerr I, Lam A, Webb HK, Kapoun AM, Kizer DE, McEnroe G, Hart B, Axon J, Murphy A, Chakravarty S, Dugar S, Protter AA, Higgins LS, Wick W, Weller M, Wong DH. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model[J]. Neuro Oncol, 2007, 9:259-270.
[4] Owens T, Bechmann I, Engelhardt B. Perivascular spaces and the two steps to neuroinflammation[J]. J Neuropathol Exp Neurol, 2008, 67:1113-1121.
[5] Perry VH. A revised view of the central nervous system microenvironment and major histocompatibility complex class Ⅱ antigen presentation[J]. J Neuroimmunol, 1998, 90:113-121.
[6] Louveau A, Harris TH, Kipnis J. Revisiting the mechanisms of CNS immune privilege[J]. Trends Immunol, 2015, 36:569-577.
[7] Mohammad MG, Tsai VW, Ruitenberg MJ, Hassanpour M, Li H, Hart PH, Breit SN, Sawchenko PE, Brown DA. Immune cell trafficking from the brain maintains CNS immune tolerance[J]. J Clin Invest, 2014, 124:1228-1241.
[8] Gorbachev AV, Kobayashi H, Kudo D, Tannenbaum CS, Finke JH, Shu S, Farber JM, Fairchild RL. CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors[J]. J Immunol, 2007, 178:2278-2286.
[9] Chow BW, Gu C. The molecular constituents of the blood-brain barrier[J]. Trends Neurosci, 2015, 38:598-608.
[10] Roopenian DC, Akilesh S. FcRn:the neonatal Fc receptor comes of age[J]. Nat Rev Immunol, 2007, 7:715-725.
[11] Gupta A, Probst HC, Vuong V, Landshammer A, Muth S, Yagita H, Schwendener R, Pruschy M, Knuth A, van den Broek M. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation[J]. J Immunol, 2012, 189:558-566.
[12] Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes[J]. Cancer Res, 2004, 64:7985-7994.
[13] Hao C, Parney IF, Roa WH, Turner J, Petruk KC, Ramsay DA. Cytokine and cytokine receptor mRNA expression in human glioblastomas:evidence of Th1, Th2 and Th3 cytokine dysregulation[J]. Acta Neuropathol, 2002, 103:171-178.
[14] Rodrigues JC, Gonzalez GC, Zhang L, Ibrahim G, Kelly JJ, Gustafson MP, Lin Y, Dietz AB, Forsyth PA, Yong VW, Parney IF. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties[J]. Neuro Oncol, 2010, 12:351-365.
[15] Jackson C, Ruzevick J, Phallen J, Belcaid Z, Lim M. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment[J]. Clin Dev Immunol, 2011:ID732413.
[16] Fontana A, Bodmer S, Frei K, Malipiero U, Siepl C. Expression of TGF-beta 2 in human glioblastoma:a role in resistance to immune rejection[J]?Ciba Found Symp, 1991, 157:232-238.
[17] Su Y, Jackson EK, Gorelik E. Receptor desensitization and blockade of the suppressive effects of prostaglandin E (2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes[J]. Cancer Immunol Immunother, 2011, 60:111-122.
[18] Tritschler I, Gramatzki D, Capper D, Mittelbronn M, Meyermann R, Saharinen J, Wick W, Keski-Oja J, Weller M. Modulation of TGF-beta activity by latent TGF-beta-binding protein 1 in human malignant glioma cells[J]. Int J Cancer, 2009, 125:530-540.
[19] Moravan MJ, Olschowka JA, Williams JP, O'Banion MK. Cranial irradiation leads to acute and persistent neuroinflammation with delayed increases in T-cell infiltration and CD11c expression in C57BL/6 mouse brain[J]. Radiat Res, 2011, 176:459-473.
[20] Takeshima T, Chamoto K, Wakita D, Ohkuri T, Togashi Y, Shirato H, Kitamura H, Nishimura T. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL:its potentiation by combination with Th1 cell therapy[J]. Cancer Res, 2010, 70:2697-2706.
[21] Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, Auh SL. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity[J]. Cancer Res, 2011, 71:2488-2496.
[22] Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting[J]. Nat Rev Immunol, 2006, 6:836-848.
[23] Gerber SA, Sedlacek AL, Cron KR, Murphy SP, Frelinger JG, Lord EM. IFN-gamma mediates the antitumor effects of radiation therapy in a murine colon tumor[J]. Am J Pathol, 2013, 182:2345-2354.
[24] Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang X, Gajewski TF, Chen ZJ, Fu YX, Weichselbaum RR. STING-dependent cytosolic DNA sensing promotes radiation-induced type Ⅰ interferon-dependent antitumor immunity in immunogenic tumors[J]. Immunity, 2014, 41:843-852.
[25] Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment[J]. Glia, 2012, 60:502-514.
[26] Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease[J]. Nat Rev Immunol, 2018, 18:225-242.
[27] Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, Samokhvalov IM, Merad M. Fate mapping analysis reveals that adult microglia derive from primitive macrophages[J]. Science, 2010, 330:841-845.
[28] Füger P, Hefendehl JK, Veeraraghavalu K, Wendeln AC, Schlosser C, Obermüller U, Wegenast-Braun BM, Neher JJ, Martus P, Kohsaka S, Thunemann M, Feil R, Sisodia SS, Skodras A, Jucker M. Microglia turnover with aging and in an Alzheimer's model via long-term in vivo single-cell imaging[J]. Nat Neurosci, 2017, 20:1371-1376.
[29] Chen Z, Feng X, Herting CJ, Garcia VA, Nie K, Pong WW, Rasmussen R, Dwivedi B, Seby S, Wolf SA, Gutmann DH, Hambardzumyan D. Cellular and molecular identity of tumor-associated macrophages in glioblastoma[J]. Cancer Res, 2017,77:2266-2278.
[30] Shi C, Pamer EG. Monocyte recruitment during infection and inflammation[J]. Nat Rev Immunol, 2011, 11:762-774.
[31] Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours[J]. Nat Rev Immunol, 2012, 12:253-268.
[32] Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation[J]. Nat Rev Immunol, 2008, 8:958-969.
[33] Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets:cancer as a paradigm[J]. Nat Immunol, 2010, 11:889-896.
[34] Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage M1-M2 polarization balance[J]. Front Immunol, 2014, 5:614.
[35] Chen H, Chong ZZ, De Toledo SM, Azzam EI, Elkabes S, Souayah N. Delayed activation of human microglial cells by high dose ionizing radiation[J]. Brain Res, 2016, 1646:193-198.
[36] Monje ML, Vogel H, Masek M, Ligon KL, Fisher PG, Palmer TD. Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies[J]. Ann Neurol, 2007, 62:515-520.
[37] Li MD, Burns TC, Kumar S, Morgan AA, Sloan SA, Palmer TD. Aging-like changes in the transcriptome of irradiated microglia[J]. Glia, 2015, 63:754-767.
[38] Kmiecik J, Poli A, Brons NH, Waha A, Eide GE, Enger PØ, Zimmer J, Chekenya M. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level[J]. J Neuroimmunol, 2013, 264:71-83.
[39] Fadul CE, Fisher JL, Gui J, Hampton TH, Côté AL, Ernstoff MS. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme[J]. Neuro Oncol, 2011, 13:393-400.
[40] Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, Sanchez-Perez L, Cheema TA, Souders NC, Herndon JE, Coumans JV, Everitt JI, Nahed BV, Sampson JH, Gunn MD, Martuza RL, Dranoff G, Curry WT, Fecci PE. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors[J]. Nat Med, 2018, 24:1459-1468.
[41] Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients[J]. Neuro Oncol, 2010, 12:7-13.
[42] Kim JY, Son YO, Park SW, Bae JH, Chung JS, Kim HH, Chung BS, Kim SH, Kang CD. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation[J]. Exp Mol Med, 2006, 38:474-484.
[43] Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection[J]. Cell, 2009, 138:30-50.
[44] Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion[J]. Nat Rev Immunol, 2015, 15:486-499.
[45] Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor[J]. Immunity, 1999, 11:141-151.
[46] Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment[J]. J Virol, 2003, 77:4911-4927.
[47] Kala M, Chrobok J, Dvorák P. A surprising finding by a surgery for lumbar intervertebral disk herniation:Ewing's sarcoma[J]. Acta Univ Palacki Olomuc Fac Med, 1987, 117:185-189.
[48] Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation[J]. J Exp Med, 2000, 192:1027-1034.
[49] Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity[J]. Nat Immunol, 2005, 6:1245-1252.
[50] Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, Anders R, Netto G, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, Drake CG. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self-and tumor-tolerance systems[J]. J Clin Invest, 2007, 117:3383-3392.
[51] Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, Powell JD, Pardoll DM, Drake CG, Vignali DA. Role of LAG-3 in regulatory T cells[J]. Immunity, 2004, 21:503-513.
[52] Wherry EJ. T cell exhaustion[J]. Nat Immunol, 2011, 12:492-499.
[53] Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, Elsamadicy AA, Cui X, Koyama S, Jackson C, Hansen LJ, Johanns TM, Sanchez-Perez L, Chandramohan V, Yu YA, Bigner DD, Giles A, Healy P, Dranoff G, Weinhold KJ, Dunn GP, Fecci PE. T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma[J]. Clin Cancer Res, 2018, 24:4175-4186.
[54] Mohme M, Schliffke S, Maire CL, Runger A, Glau L, Mende KC, Matschke J, Gehbauer C, Akyuz N, Zapf S, Holz M, Schaper M, Martens T, Schmidt NO, Peine S, Westphal M, Binder M, Tolosa E, Lamszus K. Immunophenotyping of newly diagnosed and recurrent glioblastoma defines distinct immune exhaustion profiles in peripheral and tumor-infiltrating lymphocytes[J]. Clin Cancer Res, 2018, 24:4187-4200.
[55] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12:252-264.
[56] Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway[J]. Nat Rev Immunol, 2018, 18:153-167.
[57] Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB. Immune checkpoint blockade as a potential therapeutic target:surveying CNS malignancies[J]. Neuro Oncol, 2016, 18:1357-1366.
[58] Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M, Kurscheid S, Hegi ME, Zielinski CC, Marosi C, Hainfellner JA, Preusser M, Wick W. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma[J]. Neuro Oncol, 2015, 17:1064-1075.
[59] Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma[J]. Nat Rev Neurol, 2015, 11:504-514.
[60] Collins AV, Brodie DW, Gilbert RJ, Iaboni A, Manso-Sancho R, Walse B, Stuart DI, van der Merwe PA, Davis SJ. The interaction properties of costimulatory molecules revisited[J]. Immunity, 2002, 17:201-210.
[61] Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength[J]. Immunity, 2002, 16:23-35.
[62] Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, ittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement[J]. Immunity, 1996, 4:535-543.
[63] Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1(CD80) and B7-2(CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors[J]. Immunity, 1994, 1:793-801.
[64] Riley JL, Mao M, Kobayashi S, Biery M, Burchard J, Cavet G, Gregson BP, June CH, Linsley PS. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors[J]. Proc Natl Acad Sci USA, 2002, 99:11790-11795.
[65] Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, Straus D, Samelson LE, Thompson CB, Bluestone JA. Molecular basis of T cell inactivation by CTLA-4[J]. Science, 1998, 282:2263-2266.
[66] Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S. Immunologic self-tolerance maintained by CD25(+) CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4[J]. J Exp Med, 2000, 192:303-310.
[67] Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies[J]. J Exp Med, 2009, 206:1717-1725.
[68] Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, Freeman GJ, Kuchroo VK. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease[J]. Nature, 2002, 415:536-541.
[69] Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, Chandwaskar R, Karman J, Su EW, Hirashima M, Bruce JN, Kane LP, Kuchroo VK, Hafler DA. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells[J]. Science, 2007, 318:1141-1143.
[70] Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ, Azuma M, Anderson AC, Kuchroo VK, Blazar BR. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia[J]. Blood, 2011, 117:4501-4510.
[71] Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting TIM-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity[J]. J Exp Med, 2010, 207:2187-2194.
[72] Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells[J]. Proc Natl Acad Sci USA, 2003, 100:5336-5341.
[73] Yan J, Zhang Y, Zhang JP, Liang J, Li L, Zheng L. TIM-3 expression defines regulatory T cells in human tumors[J]. PLoS One, 2013, 8:E58006.
[74] Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E, Pradilla G, Ford E, Wong J, Hammers HJ, Mathios D, Tyler B, Brem H, Tran PT, Pardoll D, Drake CG, Lim M. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas[J]. Int J Radiat Oncol Biol Phys, 2013, 86:343-349.
[75] Belcaid Z, Phallen JA, Zeng J, See AP, Mathios D, Gottschalk C, Nicholas S, Kellett M, Ruzevick J, Jackson C, Albesiano E, Durham NM, Ye X, Tran PT, Tyler B, Wong JW, Brem H, Pardoll DM, Drake CG, Lim M. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model[J]. PLoS One, 2014, 9:E101764.
[76] Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, Liu A, Sankey EW, Tam A, Xu H, Mathios D, Jackson CM, Harris-Bookman S, Garzon-Muvdi T, Sheu M, Martin AM, Tyler BM, Tran PT, Ye X, Olivi A, Taube JM, Burger PC, Drake CG, Brem H, Pardoll DM, Lim M. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas[J]. Clin Cancer Res, 2017, 23:124-136.
[77] Patel MA, Kim JE, Theodros D, Tam A, Velarde E, Kochel CM, Francica B, Nirschl TR, Ghasemzadeh A, Mathios D, Harris-Bookman S, Jackson CC, Jackson C, Ye X, Tran PT, Tyler B, Coric V, Selby M, Brem H, Drake CG, Pardoll DM, Lim M. Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma[J]. J Immunother Cancer, 2016, 4:28.
[78] Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB. PD-L1 expression and prognostic impact in glioblastoma[J]. Neuro Oncol, 2016, 18:195-205.
[79] Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma:results from exploratory phase Ⅰ cohorts of CheckMate 143[J]. Neuro Oncol, 2018, 20:674-686.
[80] Zhang L, Cheng F, Wei Y, Zhang L, Guo D, Wang B, Li W. Inhibition of TAZ contributes radiation-induced senescence and growth arrest in glioma cells[J]. Oncogene, 2019, 38:2788-2799.
[81] Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy[J]. Annu Rev Immunol, 2013, 31:51-72.
[82] Medzhitov R. Toll-like receptors and innate immunity[J]. Nat Rev Immunol, 2001, 1:135-145.
[83] Facci L, Barbierato M, Marinelli C, Argentini C, Skaper SD, Giusti P. Toll-like receptors 2,-3 and-4 prime microglia but not astrocytes across central nervous system regions for ATP-dependent interleukin-1β release[J]. Sci Rep, 2014, 4:6824.
[84] Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy[J]. Nat Med, 2007, 13:1050-1059.
[85] Ohshima Y, Tsukimoto M, Takenouchi T, Harada H, Suzuki A, Sato M, Kitani H, Kojima S. Gamma-irradiation induces P2X (7) receptor-dependent ATP release from B16 melanoma cells[J]. Biochim Biophys Acta, 2010, 1800:40-46.
[86] Ehlers G, Fridman M. Abscopal effect of radiation in papillary adenocarcinoma[J]. Br J Radiol, 1973, 46:220-222.
[87] Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated[J]. Int J Radiat Oncol Biol Phys, 2004, 58:862-870.
[88] Bramhall RJ, Mahady K, Peach AH. Spontaneous regression of metastatic melanoma-clinical evidence of the abscopal effect[J]. Eur J Surg Oncol, 2014, 40:34-41.
[89] Nelson MH, Bowers JS, Bailey SR, Diven MA, Fugle CW, Kaiser AD, Wrzesinski C, Liu B, Restifo NP, Paulos CM. Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning[J]. J Immunother Cancer, 2016, 4:6.
[90] Wen P, Reardon D, Phuphanich S, Aiken R, Landolfi J, Curry W, Zhu JJ, Glantz M, Peereboom D, Markert J, Larocca R, O'Rourke D, Fink K, Kim L, Gruber M, Lesser G, Pan E, Santos R, Pinilla C, Yu J. IMCT-20 association of survival and progression-free survival with immune response in Hla-A2+ newly-diagnosed Gbm patients in randomized double-blind placebo-controlled phase 2 trial of dendritic cell (DC) immunotherapy with ICT-107[J]. Neuro-Oncology, 2015, 17:V111-112.
[91] Zussman BM, Engh JA. Outcomes of the ACT Ⅲ study:rindopepimut (CDX-110) therapy for glioblastoma[J]. Neurosurgery, 2015, 76:N17.
[92] Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB, Sampson JH. A phase Ⅱ, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma:the ACT Ⅲ study[J]. Neuro Oncol, 2015, 17:854-861.
[93] Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT Ⅳ trial investigators. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRv Ⅲ-expressing glioblastoma (ACT Ⅳ):a randomised, double-blind, international phase 3 trial[J]. Lancet Oncol, 2017, 18:1373-1385.
[94] Ahmed N, Brawley V, Hegde M, Bielamowicz K, Wakefield A, Ghazi A, Ashoori A, Diouf O, Gerken C, Landi D, Kalra M, Yi Z, Rooney C, Dotti G, Gee A, Heslop H, Gottschalk S, Powell S, Grossman R, Wels W, Kew Y, Baskin D, Zhang J, New P, Hicks J. Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase Ⅰ trial[J]. J ImmunoTher Canc, 2015, 3(Suppl 2):11.
[95] Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA,Özgüroglu M; PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J]. N Engl J Med, 2017, 377:1919-1929.
[96] Mathios D, Kim JE, Mangraviti A, Phallen J, Park CK, Jackson CM, Garzon-Muvdi T, Kim E, Theodros D, Polanczyk M, Martin AM, Suk I, Ye X, Tyler B, Bettegowda C, Brem H, Pardoll DM, Lim M. Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM[J]. Sci Transl Med, 2016, 8:370RA180.
[97] Rosen EM, Fan S, Rockwell S, Goldberg ID. The molecular and cellular basis of radiosensitivity:implications for understanding how normal tissues and tumors respond to therapeutic radiation[J]. Cancer Invest, 1999, 17:56-72.
[98] Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, Piantadosi S; NABTT CNS Consortium. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide[J]. Clin Cancer Res, 2011, 17:5473-5480.
[99] Campian JL, Piotrowski AF, Ye X, Hakim FT, Rose J, Yan XY, Lu Y, Gress R, Grossman SA. Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide[J]. J Neurooncol, 2017, 135:343-351.
[100] Yovino S, Grossman SA. Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas[J]. CNS Oncol, 2012, 1:149-154.
[101] Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The etiology of treatment-related lymphopenia in patients with malignant gliomas:modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells[J]. Cancer Invest, 2013, 31:140-144.
[102] Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation[J]. Int J Radiat Oncol Biol Phys, 2012, 83:1306-1310.
[103] Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J]. Nature, 2015, 520:373-377.
[104] Ko EC, Benjamin KT, Formenti SC. Generating antitumor immunity by targeted radiation therapy:role of dose and fractionation[J]. Adv Radiat Oncol, 2018, 3:486-493.
[105] Papadopoulos KP, Crittenden MR, Johnson ML, Lockhart AC, Moore KN, Falchook GS, Formenti S, Carvajal RD, Leidner RS, Naing A, Rosen LS, Weiss GJ, Iii WC, Gao B, Paccaly A, Stankevich E, Trail P, Fury MG, Lowy I. A first-in-human study of REGN2810, a monoclonal, fully human antibody to programmed death-1(PD-1), in combination with immunomodulators including hypofractionated radiotherapy (hfRT)[J]. J Clinic Oncol, 2016, 34:3024. |